Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097691 | 1.00 | MEN1 (0.61) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6098698 | 0.84 | ALDH1A1 (0.70) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL17487054 | 0.83 | KMT2A (0.76) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6099735 | 0.82 | MEN1 (0.77) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6099740 | 0.82 | MEN1 (0.77) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL16024079 | 0.78 | MEN1 (0.80) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6098154 | 0.77 | MEN1 (0.58) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL6098152 | 0.77 | MEN1 (0.58) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL1962692 | 0.75 | TP53 (0.76) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL1962693 | 0.75 | TP53 (0.76) | MEN1KMT2AMAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053216-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030171387-A1 | Modulators of Rho C activity | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043961-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171387-A1 | Modulators of Rho C activity | RHOC, ROCK1, CIT | MEN1 4684/4885KMT2A 3564/4885MAPT 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.